Astrana Health, Inc. (ASTH) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Astrana Health, Inc. Do?
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. It is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1994 and is headquartered in Alhambra, California. Astrana Health, Inc. (ASTH) is classified as a small-cap stock in the Industrials sector, specifically within the Business Services industry. The company is led by CEO Brandon K. Sim and employs approximately 1,900 people. With a market capitalization of $1.4B, ASTH is one of the notable companies in the Industrials sector.
Astrana Health, Inc. (ASTH) Stock Rating — Reduce (April 2026)
As of April 2026, Astrana Health, Inc. receives a Reduce rating with a composite score of 40.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ASTH ranks #2,155 out of 4,446 stocks in our coverage universe. Within the Industrials sector, Astrana Health, Inc. ranks #340 of 752 stocks, placing it in the upper half of its Industrials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ASTH Stock Price and 52-Week Range
Astrana Health, Inc. (ASTH) currently trades at $27.63. The stock lost $0.60 (2.1%) in the most recent trading session. The 52-week high for ASTH is $34.80, which means the stock is currently trading -20.6% from its annual peak. The 52-week low is $18.08, putting the stock 52.8% above its annual trough. Recent trading volume was 275K shares, suggesting relatively thin trading activity.
Is ASTH Overvalued or Undervalued? — Valuation Analysis
Astrana Health, Inc. (ASTH) carries a value factor score of 60/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 42.28x, compared to the Industrials sector average of 28.33x — a premium of 49%. The price-to-book ratio stands at 1.95x, versus the sector average of 2.23x. The price-to-sales ratio is 0.57x, compared to 0.50x for the average Industrials stock. On an enterprise value basis, ASTH trades at 17.42x EV/EBITDA, versus 5.70x for the sector.
Overall, ASTH's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Astrana Health, Inc. Profitability — ROE, Margins, and Quality Score
Astrana Health, Inc. (ASTH) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 4.6%, compared to the Industrials sector average of 8.9%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 1.6% versus the sector average of 3.3%.
On a margin basis, Astrana Health, Inc. reports gross margins of 10.0%, compared to 35.8% for the sector. The operating margin is 3.6% (sector: 6.2%). Net profit margin stands at 1.7%, versus 3.9% for the average Industrials stock. Revenue growth is running at 96.6% on a trailing basis, compared to 6.4% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
ASTH Debt, Balance Sheet, and Financial Health
Astrana Health, Inc. has a debt-to-equity ratio of 209.0%, compared to the Industrials sector average of 70.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.40x, suggesting adequate working capital coverage. Total debt on the balance sheet is $1.05B. Cash and equivalents stand at $462M.
ASTH has a beta of 0.50, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Astrana Health, Inc. is 51/100, reflecting average volatility within the normal range for its sector.
Astrana Health, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Astrana Health, Inc. reported revenue of $2.71B and earnings per share (EPS) of $0.46. Net income for the quarter was $36M. Gross margin was 10.0%. Operating income came in at $89M.
In FY 2025, Astrana Health, Inc. reported revenue of $3.18B and earnings per share (EPS) of $0.46. Net income for the quarter was $24M. Revenue grew 56.4% year-over-year compared to FY 2024. Operating income came in at $79M.
In Q3 2025, Astrana Health, Inc. reported revenue of $956M and earnings per share (EPS) of $0.01. Net income for the quarter was $1M. Revenue grew 99.7% year-over-year compared to Q3 2024. Operating income came in at $19M.
In Q2 2025, Astrana Health, Inc. reported revenue of $655M and earnings per share (EPS) of $0.19. Net income for the quarter was $10M. Revenue grew 34.7% year-over-year compared to Q2 2024. Operating income came in at $20M.
Over the past 8 quarters, Astrana Health, Inc. has demonstrated a growth trajectory, with revenue expanding from $486M to $2.71B. Investors analyzing ASTH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ASTH Dividend Yield and Income Analysis
Astrana Health, Inc. (ASTH) does not currently pay a dividend. This is common among smaller companies in the Business Services industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Industrials dividend stocks may want to explore other Industrials stocks or use the stock screener to filter by dividend yield.
ASTH Momentum and Technical Analysis Profile
Astrana Health, Inc. (ASTH) has a momentum factor score of 31/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ASTH vs Competitors — Industrials Sector Ranking and Peer Comparison
Within the Industrials sector, Astrana Health, Inc. (ASTH) ranks #340 out of 752 stocks based on the Blank Capital composite score. This places ASTH in the upper half of all Industrials stocks in our coverage universe. Key competitors and sector peers include South Bow Corp (SOBO) with a score of 56.5/100, TSAKOS ENERGY NAVIGATION LTD (TEN) with a score of 61.4/100, Great Lakes Dredge & Dock CORP (GLDD) with a score of 56.7/100, Tri Pointe Homes, Inc. (TPH) with a score of 57.3/100, and Clear Channel Outdoor Holdings, Inc. (CCO) with a score of 52.2/100.
Comparing ASTH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ASTH vs S&P 500 (SPY) comparison to assess how Astrana Health, Inc. stacks up against the broader market across all factor dimensions.
ASTH Next Earnings Date
No upcoming earnings date has been announced for Astrana Health, Inc. (ASTH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ASTH? — Investment Thesis Summary
The quantitative profile for Astrana Health, Inc. suggests caution. The value score of 60/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 31/100, a headwind for near-term performance.
In summary, Astrana Health, Inc. (ASTH) earns a Reduce rating with a composite score of 40.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ASTH stock.
Related Resources for ASTH Investors
Explore more research and tools: ASTH vs S&P 500 comparison, top Industrials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ASTH head-to-head with peers: ASTH vs SOBO, ASTH vs TEN, ASTH vs GLDD.